New York, USA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Global Neurodiagnostics Market to Accelerate Substantially at a CAGR of ~7% by 2034 | DelveInsight
The neurodiagnostics market is experiencing steady growth, driven by the rising prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, stroke, and multiple sclerosis. Increasing demand for early and accurate diagnosis, coupled with continuous advancements in neuroimaging, electrophysiology, and biomarker-based diagnostic technologies, is accelerating market expansion. The integration of artificial intelligence and machine learning into diagnostic workflows is further improving diagnostic accuracy and efficiency. Additionally, growing healthcare investments, expanding awareness of neurological health, and improved access to advanced diagnostic services are expected to support sustained market growth over the coming years.
DelveInsight’s Neurodiagnostics Market Insights report provides the current and forecast market analysis, individual leading neurodiagnostics companies’ market shares, challenges, neurodiagnostics market drivers, barriers, trends, and key neurodiagnostics companies in the market.
Neurodiagnostics Market Summary
- 2025 Neurodiagnostics Market Size: USD 9.9 Billion
- 2034 Projected Neurodiagnostics Market Size: USD 18.5 Billion
- Neurodiagnostics Market Growth Rate (2026-2034): ~7%
- Largest Neurodiagnostics Market: North America
- Largest Product Type Segment: Systems Category
- Key Companies in the Neurodiagnostics Market: Natus Medical Incorporated, Nihon Kohden Corporation, Medtronic plc, Cadwell Industries, Compumedics Limited, EB Neuro S.p.A., Micromed S.p.A., Neurosoft, Deymed Diagnostic, Ambu A/S, Brain Products GmbH, Electrical Geodesics Inc. (EGI), NCC Medical Co., NeuroWave Systems, Neuroelectrics, Persyst Development Corporation, OpenBCI, Emotiv, NeuroSky, Advanced Brain Monitoring, and others
To read more about the latest highlights related to the neurodiagnostics market, get a snapshot of the key highlights @ https://www.delveinsight.com/report-store/neurodiagnostics-market
Key Factors Contributing to the Rise in Growth of the Neurodiagnostics Market
- Increasing Prevalence of Neurological Disorders: The growing incidence of neurological conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, stroke, and brain tumors is significantly driving demand for neurodiagnostic technologies. Early and accurate diagnosis is becoming increasingly important for improving patient outcomes and treatment planning.
- Growing Aging Population: The expanding geriatric population is more susceptible to age-related neurological disorders, creating sustained demand for diagnostic procedures. As life expectancy increases globally, healthcare systems are investing more in advanced neurodiagnostic solutions to address the rising disease burden.
- Advancements in Neurodiagnostic Technologies: Continuous innovations in electroencephalography (EEG), electromyography (EMG), magnetic resonance imaging (MRI), computed tomography (CT), and molecular imaging have improved diagnostic precision. The integration of AI, machine learning, and cloud-based analytics is further enhancing workflow efficiency and clinical decision-making.
- Rising Demand for Early Disease Detection: Healthcare providers are increasingly emphasizing early diagnosis to enable timely intervention and slow disease progression. This trend is boosting the adoption of advanced neurodiagnostic tools capable of detecting neurological abnormalities at earlier stages.
- Expansion of Minimally Invasive and Non-Invasive Diagnostics: The development of non-invasive neurodiagnostic techniques has improved patient comfort while reducing procedural risks. These technologies are gaining widespread acceptance in hospitals and diagnostic centers due to their safety, convenience, and diagnostic accuracy.
- Increasing Healthcare Expenditure and Infrastructure Development: Governments and private healthcare organizations are investing heavily in modernizing healthcare infrastructure and expanding access to advanced diagnostic equipment. These investments are accelerating the adoption of sophisticated neurodiagnostic systems across developed and emerging markets.
- Growing Research in Neuroscience and Precision Medicine: Increased funding for neuroscience research and personalized medicine is driving the development of novel diagnostic biomarkers and imaging technologies. These advancements support more accurate disease characterization and individualized treatment strategies.
- Rising Awareness of Neurological Health: Public health campaigns, patient advocacy groups, and educational initiatives are improving awareness about neurological diseases and the importance of early diagnosis. This has led to greater screening rates and increased utilization of neurodiagnostic services.
- Increasing Adoption in Outpatient and Ambulatory Settings: Portable and compact neurodiagnostic devices are enabling diagnostic testing beyond traditional hospital environments. The growing use of ambulatory diagnostic centers and home-based monitoring solutions is expanding market accessibility and improving patient convenience.
- Supportive Regulatory Approvals and Product Launches: Regulatory agencies are approving innovative neurodiagnostic devices and software at an increasing pace, while manufacturers continue introducing technologically advanced products. These developments are expanding the range of available diagnostic solutions and fostering market growth.
- Growing Integration of Artificial Intelligence and Digital Health: AI-powered image analysis, automated signal interpretation, and predictive analytics are improving diagnostic speed and accuracy while reducing clinician workload. Digital health integration is also enabling remote monitoring and tele-neurology services, further supporting market expansion.
- Increasing Burden of Traumatic Brain Injuries and Stroke: Rising cases of traumatic brain injuries resulting from road accidents, sports injuries, and falls, along with the growing global burden of stroke, are increasing the need for rapid and accurate neurodiagnostic evaluations. This trend continues to drive demand for advanced imaging and neurophysiological diagnostic technologies.
Get a sneak peek at the neurodiagnostics market dynamics @ Neurodiagnostics Market Trends
Regional Neurodiagnostics Market Insights
North America
- North America held the largest share of the global neurodiagnostics market, accounting for approximately 39% in 2025.
- The region's leadership is supported by its well-established healthcare infrastructure, widespread adoption of advanced neurodiagnostic technologies, and the strong presence of key market participants, including Natus Medical Incorporated, Nihon Kohden Corporation, and Medtronic plc.
- A growing burden of neurological disorders such as epilepsy, Alzheimer's disease, and Parkinson's disease continues to fuel demand for neurodiagnostic testing.
- Moreover, rising awareness of sleep-related disorders, favorable reimbursement policies, and sustained investments in research and innovation are expected to further strengthen the region's market position.
- The North American neurodiagnostics market is also benefiting from the growing demand for sleep disorder diagnostics, an increasing number of neurosurgical procedures, and ongoing technological innovations in neurodiagnostic equipment.
- The expanding prevalence of sleep disorders, particularly sleep apnea, has accelerated the adoption of polysomnography (PSG) systems and EEG-based sleep monitoring solutions, with growing preference for home-based and wearable diagnostic devices.
- In addition, the rising volume of neurosurgical and spinal interventions is driving greater utilization of intraoperative neurophysiological monitoring (IONM) systems, which incorporate EEG, EMG, and evoked potential technologies to enhance surgical accuracy and improve patient outcomes.
- Continued advancements in portable, AI-enabled, and integrated neurodiagnostic platforms are further supporting market expansion across both hospital and home-care settings.
Europe
- The European neurodiagnostics market is experiencing steady growth, supported by the increasing incidence of neurological disorders, a rapidly aging population, and rising investments in cutting-edge diagnostic technologies.
- Major markets, including Germany, the UK, and France, are reporting a higher prevalence of neurological conditions such as dementia, epilepsy, and stroke, driving greater demand for diagnostic modalities including electroencephalography (EEG), electromyography (EMG), and advanced neuroimaging techniques.
- The region's robust healthcare infrastructure, supportive government policies, and growing investments in neuroscience research are further fostering the adoption of next-generation neurodiagnostic solutions.
- Moreover, the incorporation of digital innovations, such as artificial intelligence-powered EEG interpretation and portable neurodiagnostic devices, is enhancing diagnostic efficiency and expanding market opportunities.
- Ongoing technological advancements and strategic developments continue to reinforce the positive growth outlook for the European neurodiagnostics market.
Asia-Pacific
- The Asia-Pacific region is becoming a key engine of growth in the neurodiagnostics market, supported by its expanding elderly population, increasing incidence of neurological disorders including epilepsy, stroke, and Parkinson’s disease, and continuous improvements in healthcare infrastructure across major economies such as China, India, and Japan.
- Higher healthcare spending, broader availability of diagnostic facilities, and growing awareness regarding the importance of early neurological disease detection are driving the demand for neurodiagnostic technologies, including EEG, EMG, and sleep diagnostic systems.
- At the same time, the increasing adoption of portable, affordable, and technologically advanced diagnostic devices is improving accessibility to neurodiagnostic services across both metropolitan and emerging regions.
- Favorable government initiatives to enhance healthcare delivery, coupled with expanding investments from domestic and international market participants, are further supporting regional market expansion.
- As a result, APAC is expected to remain the fastest-growing regional market for neurodiagnostics over the forecast period.
To know more about why North America is leading the market growth in the neurodiagnostics market, get a snapshot of the Neurodiagnostics Market Share
Recent Developmental Activities in the Neurodiagnostics Market
- In April 2026, the FDA granted 510(k) clearance to Zeto Inc. for its “Zeto New Wave” EEG system, designed for outpatient and home-based use with cloud connectivity and integrated multi-signal monitoring capabilities, improving accessibility and workflow efficiency.
- In January 2026, Empatica received FDA clearance for its EmbraceMini wearable device designed for sleep monitoring and actigraphy-based assessment, enabling remote and continuous sleep diagnostics.
- In October 2025, Natus Medical Incorporated acquired Norway-based Holberg EEG to integrate AI-driven EEG interpretation technology into its portfolio, strengthening its presence in the European market and enhancing diagnostic accuracy.
- In June 2025, the company enhanced its digital health platform with advanced physiological monitoring capabilities, supporting sleep and neurological data integration.
- In April 2025, the U.S. FDA approved Siemens Healthineers’ Magnetom Prisma Fit MRI system, which offers advanced neuroimaging capabilities and expands access to high-performance brain diagnostics.
What is Neurodiagnostics?
Neurodiagnostics refers to the collection of diagnostic techniques and technologies used to evaluate the structure, function, and health of the nervous system, including the brain, spinal cord, and peripheral nerves. These tools play a crucial role in the early detection, diagnosis, monitoring, and management of neurological disorders such as epilepsy, stroke, Parkinson’s disease, Alzheimer's disease, multiple sclerosis, neuropathies, and traumatic brain injuries. Neurodiagnostic procedures include electrophysiological tests such as electroencephalography (EEG), electromyography (EMG), nerve conduction studies (NCS), and evoked potentials (EP), as well as advanced neuroimaging modalities like magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET). With continuous advancements in imaging technology, artificial intelligence, and portable diagnostic systems, neurodiagnostics is becoming increasingly accurate, accessible, and essential for enabling timely clinical decision-making and improving patient outcomes.
| Neurodiagnostics Market Report Metrics | Details |
| Coverage | Global |
| Study Period | 2023–2034 |
| Neurodiagnostics Market CAGR | ~7% |
| Neurodiagnostics Market Size by 2034 | USD 18.5 Billion |
| Key Neurodiagnostics Companies | Natus Medical Incorporated, Nihon Kohden Corporation, Medtronic plc, Cadwell Industries, Compumedics Limited, EB Neuro S.p.A., Micromed S.p.A., Neurosoft, Deymed Diagnostic, Ambu A/S, Brain Products GmbH, Electrical Geodesics Inc. (EGI), NCC Medical Co., NeuroWave Systems, Neuroelectrics, Persyst Development Corporation, OpenBCI, Emotiv, NeuroSky, Advanced Brain Monitoring, and others |
Neurodiagnostics Market Assessment
- Neurodiagnostics Market Segmentation
- Neurodiagnostics Market Segmentation By Product Type: Systems {Electroencephalography (EEG) Systems, Electromyography (EMG) Systems, Nerve Conduction Studies (NCS) Systems, Polysomnography Systems, and Others}, Accessories and Consumables, and Software
- Neurodiagnostics Market Segmentation By Technology: Neuroimaging Technology, In-Vitro Diagnostic, and Neuroinformatics
- Neurodiagnostics Market Segmentation By Application: Epilepsy and Seizure Disorders, Sleep Disorders, Stroke and Cerebrovascular Diseases, Parkinson’s, Dementia and Alzheimer’s, and Others
- Neurodiagnostics Market Segmentation By End Users: Hospitals & Neurology Clinics, Diagnostic Laboratories, Ambulatory Surgical Centers, and Others
- Neurodiagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the neurodiagnostics market are set to emerge as the trendsetter explore @ Neurodiagnostics Market Analysis
Table of Contents
| 1 | Neurodiagnostics Market Report Introduction |
| 2 | Neurodiagnostics Market Executive Summary |
| 3 | Neurodiagnostics Market Key Factors Analysis |
| 4 | Impact Analysis |
| 5 | Regulatory Analysis |
| 6 | Neurodiagnostics Market Porter’s Five Forces Analysis |
| 7 | Neurodiagnostics Market Assessment |
| 8 | Competitive Landscape |
| 9 | Startup Funding & Investment Trends |
| 10 | Neurodiagnostics Market Company and Product Profiles |
| 11 | KOL Views |
| 12 | Project Approach |
| 13 | About DelveInsight |
| 14 | Disclaimer & Contact Us |
Interested in knowing the neurodiagnostics market share by 2034? Click to get a snapshot of the Neurodiagnostics Market Size
Related Reports
Neurotechnology Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neurotechnology companies such as Neuralink Corp., Synchron Inc., Paradromics Inc., Blackrock Neurotech LLC, Kernel Inc., Emotiv Inc., NeuroSky Inc., OpenBCI Inc., Neurable Inc., BrainCo Inc., NextMind (Snap Inc.), Bitbrain Technologies S.L., Advanced Brain Monitoring Inc., Cognionics Inc., g.tec medical engineering GmbH, Natus Medical Incorporated, Nihon Kohden Corporation, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, and others.
Neurodegenerative Disease Market
Neurodegenerative Disease Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neurodegenerative disease companies such as Eisai Co., Ltd., AbbVie Inc., Johnson & Johnson, Novartis AG, Biogen Inc., Eli Lilly and Company, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc (GSK plc), H. Lundbeck A/S, Supernus Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences, Inc., PTC Therapeutics, Inc., and others.
In Vitro Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key in vitro diagnostics companies such as F. Hoffmann-La Roche Ltd, Abbott, FUJIFILM Corporation, Sysmex Corporation, Siemens Healthcare GmbH, BD, Seegene Inc, Beckman Coulter, Inc ( Danaher Corporation), QIAGEN, bioMérieux SA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc, Cisbio (PerkinEemer), ARKRAY, Inc, Ortho Clinical Diagnostics, ACON Laboratories, Inc., Teco Diagnostics, EKF Diagnostics, Besurence GmbH, Savyon Diagnostics, HORIBA, Ltd., Palliance AB, Sugentech, Inc, Cypress Diagnostics, Salignostics, The Menarini Group, DxGen Corp, HUMAN, Nova Biomedical, Asahi Kasei Pharma Corporation, Agilent Technologies, Inc., and others.
Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics, and others.
Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
